Priority review granted to BeiGene’s Tislelizumab in China by NMPA
Category: #health  By Paroma Bhattacharya  Date: 2019-07-08
  • share
  • Twitter
  • Facebook
  • LinkedIn

Priority review granted to BeiGene’s Tislelizumab in China by NMPA

BeiGene, Co., Ltd., a commercial-stage biotechnology company recently announced that China NMPA (National Medical Products Administration) has granted priority review status to the sNDA (supplemental new drug application) for an investigational Fc-engineered anti-PD1 antibody, tislelizumab, for patients with metastatic urothelial carcinoma.

For the record, BeiGene has been developing tislelizumab as a monotherapy and in combination with other therapies for the treatment of both solid & hematologic cancers. In 2018, a New Drug Application for the drug as a potential treatment of patients with R/R (Relapsed/Refractory) CHL (Classic Hodgkin’s Lymphoma) was accepted by the NMPA & was granted a priority review status in the same year.

Urothelial carcinoma, also known as TCC (transitional cell carcinoma) is the most common type of bladder cancer. In 2018, it was estimated that 82,270 incidences of bladder cancer cases were registered in China, accounting for 15% of all incidences worldwide. Although urothelial carcinoma is most common in the bladder, it can occur in other parts of the urinary system as well.

Wendy Yan, Senior VP, Global Head of Regulatory Affairs, at BeiGene, Co., Ltd., was reported to state that the company’s first priority review granted by the NMPA was for a solid tumor indication for a PD-1 antibody for bladder cancer & now, tislelizumab has become the second to receive priority review by the NMPA. Moreover, zanubrutinib was granted two priority reviews in China for treatment of various B cell malignancies.

BeiGene’s regulatory team has been closely working with the National Medical Products Administration, as NMPA reviews applications for treating patients with hematologic cancers & solid tumors. The company is looking forward to treating patients with metastatic urothelial carcinoma, with the new drug, Yen added.

Reportedly, the supplemental new drug application for tislelizumab as a potential treatment for patients with metastatic urothelial carcinoma was accepted by the NMPA in May 2019. The drug is reinforced by clinical, non-clinical & CMC data packages including the results from a pivotal Phase 2 study of the drug in 113 Chinese & Korean patients with metastatic urothelial carcinoma.

Source credits: http://ir.beigene.com/news-releases/news-release-details/priority-review-granted-beigenes-supplemental-new-drug



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

Aino Health inks deal with 55BirchStreet to expand in German markets
Aino Health inks deal with 55BirchStreet to expand in German markets
By Paroma Bhattacharya

Reports confirm that Sweden’s Aino Health and 55BirchStreet, a Germany-based digital consulting firm, have recently signed a new partnership agreement. 55BitchStreet will sell implementation services and licenses...

Visa acquires Payworks for an integrated payment acceptance solution
Visa acquires Payworks for an integrated payment acceptance solution
By Paroma Bhattacharya

Visa, the financial services company recently announced acquisition of Payworks, the Munich-based makers of payment gateway software for the POS (point of sale). The company plans to integrate cloud-based solution of P...

MacroGenics, I-Mab team up to develop & market enoblituzumab in China
MacroGenics, I-Mab team up to develop & market enoblituzumab in China
By Paroma Bhattacharya

MacroGenics, Inc. and I-Mab Biopharma, a U.S. and China based clinical-stage biopharmaceutical company that is committed to discover and develop biologics in autoimmune and immune-oncology diseases, have recently announc...